Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01260467 · ClinicalTrials.gov registry record · Phase 2
Memantine for Recurrent Glioblastoma
A Phase 2 study, sponsored by University of Rochester.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT01260467: Clinical Trial Phase 2 study, sponsored by University of Rochester.
NCT01260467 is a Phase 2 study that was terminated before completion, run by University of Rochester. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01260467, a Phase 2 study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of conditions, such as Alzheimer's disease, but it has not yet been evaluated in the treatment of brain tumors. The investigators will also be determining how common it is for patients with brain tumors to have side effects to memantine. Memantine will be taken by mouth twice a day.
Interventions
- DRUG memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2010-11 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Why NCT01260467 stopped before completion
NCT01260467 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which memantine is the first listed.
NCT01260467 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01260467 about?
NCT01260467 is a clinical study titled "Memantine for Recurrent Glioblastoma". The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of condi...
What is the current status of trial NCT01260467?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2010-11. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01260467?
The interventions under investigation include: memantine (DRUG).
Who is sponsoring clinical trial NCT01260467?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01260467's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia